ResMed Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
ResMed wird ein jährliches Gewinn- und Umsatzwachstum von 13.5% bzw. 7.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22.2% betragen.
Wichtige Informationen
13.5%
Wachstumsrate der Gewinne
12.8%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.7% |
| Wachstumsrate der Einnahmen | 6.6% |
| Zukünftige Eigenkapitalrendite | 22.2% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 21 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26ResMed goes ex dividend tomorrow
Feb 07ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06ResMed: The GARP Story Continues, Technicals Showing Vital Signs
Jan 26Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention
Jan 23We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease
Dec 28Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)
Dec 16ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends
Nov 14Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 6/30/2026 | 5,395 | 1,378 | 1,416 | 1,522 | 19 |
| 6/30/2025 | 5,036 | 1,240 | 1,282 | 1,391 | 22 |
| 6/30/2024 | 4,677 | 1,024 | 1,154 | 1,261 | 22 |
| 3/31/2024 | 4,584 | 958 | 1,071 | 1,199 | N/A |
| 12/31/2023 | 4,504 | 890 | 944 | 1,079 | N/A |
| 9/30/2023 | 4,375 | 907 | 792 | 935 | N/A |
| 6/30/2023 | 4,223 | 898 | 559 | 693 | N/A |
| 3/31/2023 | 4,016 | 863 | 408 | 535 | N/A |
| 12/31/2022 | 3,763 | 809 | 222 | 370 | N/A |
| 9/30/2022 | 3,624 | 786 | 305 | 461 | N/A |
| 6/30/2022 | 3,578 | 779 | 195 | 351 | N/A |
| 3/31/2022 | 3,539 | 779 | 344 | 498 | N/A |
| 12/31/2021 | 3,444 | 522 | 446 | 577 | N/A |
| 9/30/2021 | 3,349 | 500 | 397 | 527 | N/A |
| 6/30/2021 | 3,197 | 475 | 620 | 737 | N/A |
| 3/31/2021 | 3,091 | 457 | 733 | 840 | N/A |
| 12/31/2020 | 3,092 | 699 | 774 | 884 | N/A |
| 9/30/2020 | 3,028 | 680 | 684 | 784 | N/A |
| 6/30/2020 | 2,957 | 622 | 696 | 802 | N/A |
| 3/31/2020 | 2,892 | 513 | 505 | 614 | N/A |
| 12/31/2019 | 2,784 | 455 | 420 | 514 | N/A |
| 9/30/2019 | 2,699 | 419 | 487 | 573 | N/A |
| 6/30/2019 | 2,607 | 405 | 382 | 459 | N/A |
| 3/31/2019 | 2,525 | 446 | 374 | 447 | N/A |
| 12/31/2018 | 2,455 | 450 | 385 | 456 | N/A |
| 9/30/2018 | 2,405 | 335 | 390 | 459 | N/A |
| 6/30/2018 | 2,340 | 316 | 434 | 505 | N/A |
| 3/31/2018 | 2,273 | 307 | 444 | 516 | N/A |
| 12/31/2017 | 2,196 | 285 | N/A | 434 | N/A |
| 9/30/2017 | 2,125 | 352 | N/A | 422 | N/A |
| 6/30/2017 | 2,067 | 342 | N/A | 414 | N/A |
| 3/31/2017 | 2,029 | 324 | N/A | 417 | N/A |
| 12/31/2016 | 1,968 | 327 | N/A | 474 | N/A |
| 9/30/2016 | 1,893 | 346 | N/A | 510 | N/A |
| 6/30/2016 | 1,839 | 352 | N/A | 548 | N/A |
| 3/31/2016 | 1,773 | 357 | N/A | 505 | N/A |
| 12/31/2015 | 1,742 | 357 | N/A | 471 | N/A |
| 9/30/2015 | 1,710 | 353 | N/A | 421 | N/A |
| 6/30/2015 | 1,679 | 353 | N/A | 383 | N/A |
| 3/31/2015 | 1,641 | 353 | N/A | 399 | N/A |
| 12/31/2014 | 1,616 | 352 | N/A | 409 | N/A |
| 9/30/2014 | 1,578 | 348 | N/A | 387 | N/A |
| 6/30/2014 | 1,555 | 345 | N/A | 391 | N/A |
| 3/31/2014 | 1,554 | 331 | N/A | 400 | N/A |
| 12/31/2013 | 1,540 | 325 | N/A | 406 | N/A |
| 9/30/2013 | 1,532 | 317 | N/A | 415 | N/A |
| 6/30/2013 | 1,514 | 307 | N/A | 403 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: RMDDas prognostizierte Gewinnwachstum (13.5% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: RMDDie Erträge des Unternehmens (13.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: RMDDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: RMDDie Einnahmen des Unternehmens (7.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: RMDDie Einnahmen des Unternehmens (7.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: RMDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22.2%)